Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VX-708 + itraconazole is a combination of two drugs: VX-708, a small molecule inhibitor developed by Vertex Pharmaceuticals that blocks voltage-gated sodium channels (VGSCs), and itraconazole, an antifungal agent commonly known for potentiating drug-drug interactions via CYP3A4 inhibition. VX-708 is under investigation for nervous system diseases, particularly pain, with phase 1 clinical trials evaluating its safety and pharmacokinetics in healthy participants. The combination with itraconazole is likely employed to study potential pharmacokinetic interactions, as itraconazole is a strong CYP3A4 inhibitor and may alter the metabolism of VX-708, but there are no approvals or specific disease indications reported for this exact combination.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on VX-708 + itraconazole.